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Abstract
Background: hCG is a wonder. Firstly, because hCG is such an extreme molecule. hCG is the most acidic
glycoprotein containing the highest proportion of sugars. Secondly, hCG exists in 5 common forms. Finally, it has
so many functions ranging from control of human pregnancy to human cancer. This review examines these
molecules in detail.
Content: These 5 molecules, hCG, sulfated hCG, hyperglycosylated hCG, hCG free beta and hyperglycosylated free
beta are produced by placental syncytiotrophoblast cells and pituitary gonadotrope cells (group 1), and by
placental cytotrophoblast cells and human malignancies (group 2). Group 1 molecules are both hormones that act
on the hCG/LH receptor. These molecules are central to human menstrual cycle and human pregnancy. Group 2
molecules are autocrines, that act by antagonizing a TGF beta receptor. These molecules are critical to all advanced
malignancies.
Conclusions: The hCG groups are molecules critical to both the molecules of pregnancy or human life, and to the
advancement of cancer, or human death.
Background
Let’s get to the point, why do we call human chorionic
gonadotropin (hCG) the wonder of today’s science.
Firstly, hCG is an extreme molecule. It is the most acid
protein in humans, some hCG variants have a peak iso-
electric point (pI) stretching to pI 3.1. hCG variants are
the most sialylated glycoproteins with up to 15 sialic
acid residues per molecule. hCG variants are the most
glycosylated of glycoproteins, hCG containing 30% sugar
by molecular weight, hyperglycosylated hCG containing
39% sugar and hyperglycosylated hCG free ß-subunit
containing 42% sugar by molecular weight. Finally, with
its extreme molecular weights, hCG is the longest circu-
lating molecule in human blood with a circulating half
life of 36 hours. Secondly, as described in this review,
there are amazingly 5 unique variants of hCG, each hav-
ing identical amino acid sequence, produced by different
cells and having independent functions. These are hCG,
sulfated hCG, hyperglycosylated hCG, hCG free ß-subu-
nit and hyperglycosylated hCG free ß-subunit. There is
no other molecule like hCG.
Finally, hCG and its variants have an incredibly wide
spectrum of biological functions. These range from
hyperglycosylated hCG and pregnancy implantation and
placental development, to hyperglycosylated hCG and
hCG and hemochorial placentation. They also include
hCG and fetal and uterine growth and numerous other
key functions during pregnancy. Sulfated hCG is pro-
duced by the pituitary in women and controls steroido-
genesis during the menstrual cycle and ovulation of the
oocyte. Fascinatingly, a hyperglycosylated hCG/hCG free
ß pathway is the center-point of all advanced human
cancer biology, driving cancer growth, cancer invasion
and cancer malignancy. This is not forgetting the key
evolutionary role that chorionic gonadotropin variants
play in the evolution of humans, most notably develop-
ment of the hemochorial placentation system, that sup-
ports the development of the human brain. You could
call hCG and its variants the everything molecules.
A common question is why are the 5 independent var-
iants of hCG all called hCG. This is because they all
s h a r eac o m m o na-subunit and ß-subunit amino acid
sequence.
I remember when I first discovered hyperglycosylated
hCG as an hCG variant back in 1977 [1]. I first named
it “invasive trophoblast antigen” b e c a u s ew ek n e wa t
that time that it independently drove implantation of
pregnancy and invasion by choriocarcinoma cells.
Within 2 years I received an official letter from the
World Health Organization instructing me to rename it Correspondence: larry@hcglab.com
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tains hCG amino acid sequence. I renamed it hypergly-
cosylated hCG based on its structure.
Research by Laub and Jennissen [2] and Lehnert and
Akhurst [3] showed that hCG ß-subunit was part of the
transforming growth factor ß (TGFß) oncoprotein family
of molecules. Lapthorn and collegues determined the 3
dimension structure of the hormone hCG [4], and
showed a 4 peptide cystine knot structure in the ß-sub-
u n i tw a sc o m m o nt oT G F ß( F i g u r e1 ) .I ti sw e l le s t a b -
lished that the hormone hCG produced in pregnancy
[5] and the sulfated variant of hCG produced by the
pituitary [6], act on an hCG/luteinizing hormone (LH)
receptor to evoke a response. Interestingly, hyperglyco-
s y l a t e dh C Ga n dh C Gf r e eß - s u b u n i th a v eb e e ns h o w n
to be autocrines and to function separately, binding and
antagonizing a TGFß receptor on the cells that produce
these hCG forms [7,8]. So another wonder, hCG and its
variants have two very different receptor binding sites.
Here we examine hCG and it variants, the wonders of
today’s science.
hCG, hyperglycosylated hCG, hemochorial placentation
and evolution
A major function of hCG during pregnancy can be
described as driving hemochorial placentation, or the
efficient method whereby humans drive nutrient transfer
to the fetus. hCG, fetal hCG and hyperglycosylated hCG
seeming have many critical roles during pregnancy (See
Section hCG, hyperglycosylated hCG and pregnancy).
Almost every medical text book sold today describe the
sole function of hCG as driving luteal steroidogenesis.
This is a very out of date description of hCG, summar-
izing research in the 1910s, 1920s and 1930s [9-12],
b o o k ss u r e l ym u s tb em o r eu pt od a t et h a nt h i sp e r i o d .
Over 100 publications in the 1970s-2010s describe and
Figure 1 The three dimensional structure of deglycosylated hCG as shown by X-ray defraction [4]. O and N mark O-linked and N-linked
oligosaccharides and * marks the site of the cystine knot, common to TGFß. Grey is a- and black is ß-subunit.
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Why is everything so out of date? Looking at the section
of this review on hCG function during pregnancy, if
t h e r ei so n l yr o o mt od e s c r i b ej u s to n eo ft h em a n y
functions it should be driving hemochorial placentation
as described here, and not just maintaining progesterone
production by the corpus luteum for 3-4 weeks.
It is well established that hyperglycosylated hCG
drives invasion and implantation by placental tropho-
blastic cell deep into the myometrium of the uterus
[13-16]. Hyperglycosylated hCG drives cytotrophoblast
cell growth [8,13,14,16,17], and hCG promotes the
fusion and differentiation of peripheral cytotrophoblast
cells, where the blood supply is, to syncytiotrophoblast
cells [17,18]. Hyperglycosylated hCG and hCG lead the
implantation of placenta tissue into the uterus and the
formation of villous trophoblast tissue. As illustrated in
Figure 2 panel A, implanted blastocysts form columns
of cytotrophoblast cells. Columns extend under the
influence of hyperglycosylated hCG. As illustrated in
panels B and C, hCG promotes differentiation of periph-
eral cells to active syncytiotrophoblast cells, closest to
the circulation. Shape of syncytiotrophoblast cells forces
arm formation and folding in developing villi (Figure 2
panels C and D). Taken together this generates villous
trophoblastic tissue (panel D).
While hCG and hyperglycosylated hCG force villous
trophoblast tissue formation, hCG promotes the devel-
opment and growth of uterine spiral arteries [19-26].
Angiogenesis forces the protrusion of arteries to reach
invading villous trophoblast tissue [19-26]. hCG also
promotes the formation of the umbilical circulation in
villous tissue and the formation of the umbilical cord
[27-32]. While there is no clear evidence of how placen-
tal villi, the maternal uterine spiral arteries and fetal
umbilical circulation are tied together to activate hemo-
chorial placentation, all the component of hemochorial
placentation are clearly hCG and hyperglycosylated hCG
controlled. Figure 3 shows a human placenta and active
hemochorial placentation. Histology shows that hemo-
chorial placentation only becomes active by 10 weeks
gestation. As illustrated in Figure 3, maternal blood fills
the decidua parietalis chambers. Nutrients are passaged
accross syncytiotrophoblast cells and into placental villi
and into the developed fetal umbilical circulation.
Hyperglycosylated hCG functions in implantation are
proven [13-16]. That hyperglycosylated hCG drives cyto-
trophoblast growth is shown and confirmed
[8,13,14,16,17]. That hCG promotes the fusion of per-
ipheral cytotrophoblast cells to syncytiotrophoblast cells
is also proven [18]. That hCG drive uterine artery angio-
genesis is demonstrated and confirmed multiple times
Figure 2 Formation of villous trophoblast. A. Cytotrophoblast
columns in early implanted embryo. B. Extension of columns and
differentiation of peripheral cells. B. and C. Folding of extensions
caused by shape of syncytiotrophoblast cells. C and D formation of
trophoblastic villi. No vascular supply, spiral arteries or fetal
vasculature is shown.
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has been demonstrated [27-32]. Putting all these syn-
thetic facts together, putting villous trophoblast tissue
with maternal spiral arteries with fetal uterine circula-
tion and you have hemochorial placentation. Clearly, the
combination of hCG and hyperglycosylated hCG drive
all event leading to hemochorial placentation [14]. This
i ss u g g e s t e d ,h o w e v e r ,b u ti th a sn o tb e e np r o v e n .A s
described in Section hCG, Hyperglycosylated hCG,
Hemochorial Placentation and Evolution, human hCG is
dramatically different to primate hCG. Can we prove
that hCG and hyperglycosylated hCG drive hemochorial
placentation in humans. No, the research would be
unethical. The only evidence that hCG related molecules
are the driving force of hemochorial placentation is the
first appearance of invasive hemochorial placentation in
early simian primates. Primates first evolved 80 million
years ago, early simian primates evolved just 37 million
years. Interestingly, chorionic gonadotropin (CG) and
hyperglycosylated CG first evolved in this same species.
The logical reason that hemochorial placentation devel-
oped is the parallel evolution of its driving signal CG
and hyperglycosylated CG.
Assuming that CG and hyperglycosylated CG drive
hemochorial placentation during pregnancy (see Section
hCG, Hyperglycosylated hCG, Hemochorial Placentation
and Evolution) we examine human and primate models
(Table 1). Table 1 quotes numerous evolution publica-
tions [33-44]. As illustrated, prosimian primates, exam-
ple: lemur, produced LH in pregnancy, biopotency 1X.
This primate used inefficient non-implanting epithelio-
chorial placentation to manage pregnancy. This primate
had a tiny brain, only 0.07% (
1/1428 th) of body weight.
With more advanced early-simian primates, example:
old world monkey, evolved CG from a deletion muta-
tion in LH. CG was produced by fused
Figure 3 Human placental hemochorial placentation. While hCG and hyperglycosylated hCG force villous trophoblast tissue formation
[13-17], hCG promotes the development and growth of uterine spiral arteries [19-26]. Angiogenesis forces the protrusion of arteries to reach
invading villous trophoblast tissue [19-26]. hCG also promotes the formation of the umbilical circulation in villous tissue and the formation of the
umbilical cord [27-32]. All linked together, villous trophoblast tissue, maternal spiral artery blood and fetal umbilical circulation and you have
hemochorial placentation, efficient fetal nutrient exchange, as illustrated. In hemochorial placentation, spiral artery bring maternal blood into one
of 4-7 hemochorial placentation chambers. Blood fills the chamber, nutrients (oxygen/glucse/amino acids) them pass across syncytiotrophoblast
cells into villous side-arms or floating villi. They are then rapidly absorbed by the umbilical circulation.
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produced by cytotrophoblast stem cells [7,45]. With the
evolution of CG and hyperglycosylated CG the early-
simian primate developed hemochorial placentation
(Table 1). The initial CG produced by this species was
deficient in acidity with only 5 acidic oligosaccharides. It
has only a 2.4 h calculated circulating 1/2-life (Table 1)
or had only 7.3X greater potency than prosimian pri-
mate placental LH. Early simian hyperglycosylated CG
had only the potency to implant placenta through the
thickness of the uterine inner lining or decidua. Hemo-
chorial placentation in early-simian primate was barely
more efficient than placentation in prosimian primates,
leading to the development of a brain 0.17% (
1/588 th) of
body mass (Table 1) [33-44].
With advancing evolution came advanced simian pri-
mates, example: orangutan. Following mutation in the
CG genes, advanced simian primates produced a more
acidic CG with 6 acidic oligosaccharides. This had a cal-
culated circulating 1/2-life of 6 hours (Table 1) or had a
biopotency of 18X more than prosimian LH. With it
extra biopotency hyperglycosylated CG implanted this
placenta through the decidua and to 10% of the width
of the uterine wall or myometrial muscle. This species
had significantly more potent hemochorial placentation
leading to the development of a brain of 0.74% of body
mass (Table 1) [33-44]. Humans evolved after many
mutations in the hCG genes. This led to a super acidic
hCG, pI 3.5 with 8 acidic oligosaccharides. This human
hCG is the most acidic glycoprotein with the highest
proportion of sugars occurring in any primate or in
humans. This super-hCG raised the circulating 1/2-life
to an incredible 36 hours, or to a biopotency of 109X
over prosimian LH. It is this super hCG and super-
hyperglycosylated hCG that drove implantation to as
deep as 1/3
rd the thickness of the myometrium (Table
1), and drove hemochorial placentation to the extreme
of efficiency. It was this super-hCG and this hemochor-
ial placentation that permitted the development of the
2.4% of body mass human brain.
The mechanism whereby humans developed ultra-effi-
cient placentation has defied evolutionary scientist for
many years [37-39]. This is all explained by the evolu-
tion of CG (biopotency 7, 3X), and the advancing evolu-
tion of CG, early-simian primate (biopotency 18X),
advanced simian primate (18X) and humans (109X). In
the human fetus, developing the large brain is not easy,
it uses 60% of transferred glucose and oxygen, leaving
the development of some human organs lacking in
nutrients [37-39].
In many respects this review of the role of CG and
hyperglycosylated CG in human evolution does not end
at this point. Recent research shows that these potent
implantation and growth factors are at the root of preg-
nancy failures in humans (see Section Hyperglycosylated
hCG, Failing Pregnancy and Hypertense Pregnancy).
Also human malignancies take advantage of these
super-potent invasion and growth factors in the human
genome to stimulate growth and invasion of all
advanced human malignancies. This is discussed in Sec-
tion Hyperglycosylated hCG, hCG free ß-subunit and
Cancer. CG is a wondrous molecule that seemingly was
only generated to advance evolution to humans. Unfor-
tunately humans have to live with the terrors of this
wondrous molecule in their genome.
hCG, hyperglycosylated hCG and pregnancy
hCG is a hormone with multiple functions during preg-
nancy. hCG acts on a joint hCG/LH receptor through a
cyclic AMP intermediate to elicit responses. Figure 4.
presents the representative structure of pregnancy hCG,
a glycoprotein of molecular weight 37,180. I say repre-
sentative in that variance in structures is apparent [1].
The a-subunit of hCG comprises 92 amino acids and 2
Table 1 Parallelisms between placental implantation and hemochorial placentation in primates, sugar structure on CG
or LH, and relative brain masses
Species Placentation
characteristics
Depth of
Invasion
Molecule produce; # oligosaccharides (oligos); pI of
dimer; circulating 1/2-life; relative biopotency
Brain mass(%
body weight)
First appearance
(million years ago)
Humans Hemochorial 1/3 rd
myometrium
CG; 8 oligos; pI 3.5; 1/2-life 36 h, 109X 2.4% 0.1
Advanced
simian
primates
Hemochorial 1/10th
myometrium
CG; 6 oligos; pI 4.9; 1/2-life 6 h; 18X 0.74% 20
Early simian
primates
Hemochorial through
decidua
CG; 5 oligos; pI 6.3; 1/2-life 2.4 h; 7.3X 0.17% 37
Prosimian
primate
Epitheliochorial non-
implanting
LH; 3 oligos; pI 9.0; 1/2-life 0.33 h; 1X 0.07% 55
The circulating 1/2-life of Advanced simian primate and Early simian primate CG was calculated using an equation that consider number of oligosaccharides on
LH and human CG and the known circulating 1/2 life. C1/2 is circulating 1/2-life and number of oligosaccharides is #O, CR = 2.4
#O x 1.9. Table summarizes
published data (34-45)
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unit comprises 145 amino acids, 2 N-linked (Asn-linked)
and 4 O-linked (Ser-linked) oligosaccharides [46].
hCG is measured during pregnancy by either the total
hCG test, which supposedly measured all hCG variants
plus its ß-subunit, or by an intact hCG assay, which
supposedly measured dimeric molecules only. I say sup-
posedly in that most laboratory total hCG tests sold
today, invariably detect hCG, hCG free ß-subunit and
other hCG degradation products and variants [47]. It is
assumed that a similar variability occurs with intact
hCG assays. I recommend one automated hCG test, the
Siemens Immulite series of hCG test. This use two anti-
bodies to the core of ß-subunit and detects most hCG
degradation products and variants on a equi-molar basis
[47].
Table 2 shows serum hCG concentration during preg-
nancy as measured by the Siemens Immulite 1000 assay.
Total hCG concentration rises from pregnancy implan-
tation (3
rd week of gestation) to a peak at 10 weeks of
gestation. hCG levels rise exponentially during the first
7 weeks of pregnancy, increasing approximately 12-fold
every week or 1.52-fold every day or 2.3-fold every two
days. Total hCG concentration declines slowly from the
Figure 4 The three dimensional structure of hCG [4]. In order to form crystals hCG was first deglycosylated. hCG and hyperglycosylated hCG
have identical amino acid sequence [1], yet vary in function. hCG binds the hCG/LH receptor while hyperglycosylated hCG antagonizes a TGFß
receptor [6-8]. As such the glycosylation (all removed) has to make a structural difference to the two hCG forms. This difference is not shown.
Oligosaccharide are added to the three dimensional structure assuming the carbohydrate structure observation of Elliott et al. [1].
Oligosaccharides are charged so must project towards the surface of the molecule. L in oligosaccharides is N-acetylgalactosamine, A is N-
acetylglucosamine, S is sialic acid or N-acetyl-neuraminic acid, G is galactose, M is mannose and F is fucose.
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concentration reach 30% of peak at 15 weeks and 18%
of peak at 20 weeks, and then hover close to 18% peak
levels until term [48].
hCG levels vary extraordinarily widely between preg-
nancies [48]. hCG concentration varies among individual
and among pregnancies from 0.21 ng/ml to 173 ng/ml
in the 4
th week of gestation (variation 824X), and varies
from 1.86 ng/ml to 1,308 ng/ml in the 5
th week of
gestation (variation 704X) (Table 2). This variation can
be attributed to poor dating of pregnancy, dating to the
first day of the last menstrual period, rather than to the
day of true start of pregnancy or implantation. The var-
iation can also be attributed to varying hCG doubling
rate among syncytiotrophoblast cells in individual preg-
nancies [48]. Seemingly, hCG levels rise differently
among different pregnancies. As found, the spare recep-
tor theory explains how pregnancies cope with such
extreme variations in concentration. Under the spare
receptor theory, when a small proportion of receptors is
activated it may yield similar cellular response to when
all receptors are activated [49-51]. This is due to pla-
teaus in receptor G protein and cyclic AMP response
[49-51]. Also down-regulation [52-54] can explain how
a pregnancy accommodates wide variation in hCG con-
centration. A high concentration of hCG, for instance,
may decrease the number of receptor on cells by
degrading the receptor transcript rate.
hCG assays have evolved through a long history
[55-60] (Table 3). The first pregnancy assay or hCG test
was the famous Zondek-Aschein Test described in 1930
[55]. The Aschheim-Zondek test was based upon the
observation that when urine from a female in the early
months of pregnancy is injected into immature female
mice, the ovaries of the mice significantly enlarge and
showed follicular maturation. The test was considered
reliable, with an error rate of less than 2%. This test was
only replaced in 1960 with the induction of the first
immunological hCG or pregnancy test, the antibody
agglutination test [56] (Table 3). In this test, serum or
urine was added to a tube and antibody added. When
hCG was present antibody-antigen aggregates were
f o r m e d .T h e s eg e n e r a t eac l o u d yo rp r e c i p i t a t e d
solution.
In 1967 the hCG radioimmunoassay replaced the
agglutination test [57] (Table 3). The radioimmunoassay
(RIA) was a much more sensitive and quantitative preg-
nancy test. In an RIA, a small but known amount of
radio-iodinated hCG competed with the unknown
serum or urine hCG in binding a limiting quantity of
antibody. The antibody was precipitated and radioactiv-
ity measured. The lower the radioactivity the higher the
unknown concentration of hCG. Unfortunately, due to
the common a-subunit on hCG and LH, the hCG RIA
recognized both hCG and LH. In 1972 the hCGß RIA
w a si n t r o d u c e d[ 5 8 ]( T a b l e3 ) .T h i sw a st h ef i r s tp r e g -
nancy test detecting only hCG.
In 1984 I saw the introduction of a new hCG antibody
technology, the immunometric assay [59] (Table 3).
Simply explained, an antibody to one immunological
site on hCG (i.e. anti a-subunit) was immobilized on
beads or on a tube. Blood or urine was added and this
antibody extracted hCG, the antigen, from the solution.
An antibody to a second separate site (i.e. anti ß-subu-
nit) was labeled with a radioactivity or other tracer. This
antibody, the tracer antibody, was added to the mix, it
Table 2 Concentration of total hCG and hyperglycosylated hCG (hCG-H) in 496 serum samples from 310 women with
term pregnancies measured using the Siemens Immulite 1000 total hCG assay
Gestation age (weeks since start of
menstrual period)
N Median Total
hCG ng/ml
Range Total hCG ng/
ml (variation)
Median hCG-H
ng/ml
Range hCG-H ng/ml
(variation)
hCG-
H%
3-weeks (3 weeks 0 days - 6 days) n = 42 0.26 (16 of 42 <
0.1 ng/ml)
0.04 - 5.5 0.20(16 of 42 <
0.1 ng/ml)
0.01 - 6.45 (645X) 87%
4 weeks n = 42 3.4 0.21 - 173 (824X) 2.5 0.18 - 160 (888X) 51%
5 weeks n = 67 65 1.86 - 1308 (704X) 8.6 0.96 - 698 (731X) 43%
6-weeks n = 29 252 3.80 - 855 (225X) 86 0.76 - 629 (827X) 36%
7 weeks n = 30 3,278 203 - 7,766 (38X) 359 27 - 931 (34X) 16%
8 weeks n = 33 4,331 1,064 - 10,057 (9.4X) 386 67 - 1050 (15.6X) 7.0%
9 weeks n = 24 5,832 1,031 - 11,586 (11.2X) 430 102 - 1158 (11.3X) 5.1%
10 weeks n = 20 10,352 1,952 - 19,958 (10.2X) 521 188 - 1855 (9.9X) 4.3%
11 - 13 weeks n = 41 5,953 1,440 - 15,318 (10.6X) 137 24 - 330 (13.7X) 2.3%
14 - 17 weeks n = 57 2,934 311 - 4,757 (15.2X) 26 6.7 - 129 (19.3X) 1.3%
18 - 26-weeks n = 62 1,931 210 - 6,223 (30.3X) 15.8 5.3 - 95 (17.9X) 0.65%
27 - 40 weeks n = 49 1,911 184 - 8,530 (46.4X) 2.95 0.3 - 12.2 (40.6X) 0.14%
Data from 50 pregnancies that failed due to miscarriage were excluded from this table. Pregnancies which failed to implant in early pregnancy (total hCG < 0.1
ng/ml) are indicated in parenthesis
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immobilized antibody-hCG-tracer antibody-label com-
plex was formed. The tracer antibody permitted quanti-
tation of the bound antigen. The following years saw a
need to automate and speed up assays, and to develop
new tracers other than radioiodine. Chemiluminescence
was discovered, where by a tracer emits light with lim-
ited emission of heat, as the result of a chemical reac-
tion. In 1995 an automated chemiluminescent hCG
assay was introduced [60]. Today, 2011, most laboratory
hCG tests are automated and are immunometric assays
using the chemiluminescent principal.
As described in Section hCG, hyperglycosylated hCG,
hemochorial placentation and evolution, hCG drives
uterine angiogenesis, umbilical circulation and hemo-
chorial placentation. As described in Section hCG,
hyperglycosylated hCG and pregnancy, a form of hCG
seemingly drives fetal growth during pregnancy. hCG
variants do as the title claims, act as a wonder molecule
doing just about everything in pregnancy. Functions
range from controlling uterine, fetal and placental
growth during pregnancy, to protecting pregnancy from
myometrial contraction, from immuno-rejection, and
from macrophage rejection. All the established hCG and
hyperglycosylated hCG functions during pregnancy are
listed in Table 4[6,9-11,13-32,61-91].
The original biological activity of hCG was first
revealed in the 1920s [9-11]. That hCG takes over from
LH in promotion of progesterone production by ovarian
corpus luteal cells in pregnant women was shown in the
nineteen sixties [6,88] (Table 4). As we know today,
hCG only promotes progesterone production for 3-4
weeks following pregnancy implantation. This function
is active for less than 10% of the length of pregnancy.
As shown in Table 2, hCG reaches a peak at 10 weeks
of gestation, or almost one month after progesterone
promotion is complete, then continues to be produced
through the length of pregnancy. Clearly, progesterone
production is not the principal function of hCG even
though this is the hCG function highlighted in most
medical text books.
Four independent research groups show that hCG
promotes an anti-macrophage inhibitory factor or a
macrophage migration inhibitory factor. This is a cyto-
kine that modulates the immune response during preg-
nancy. This reduces macrophage phagocytosis activity at
the placenta-uterus interface, preventing destruction of
the foreign fetoplacental tissue by the mothers macro-
phage system [62-64]. Four other groups have shown
that hCG may directly suppress any immune action
against the invading foreign tissue by the mother
[65-67,89]. All told, hCG appears to be important in
preventing rejection of fetoplacental tissue during preg-
nancy [62-67,89]. Most observations suggest that hCG
has an inhibitory or suppressive function on macro-
phage activity. One group, Wan et al. [64] demonstrated
that chorionic gonadotropin can directly enhance innate
immunity by stimulating macrophage function.
Multiple groups have found hCG/LH receptor in the
myometrium of the uterus. It has been indicated by two
groups that uterine growth in line with fetal growth is
controlled by hCG [68,69]. Four other groups have
shown that hCG relaxes myometrial contractions during
pregnancy. hCG acts on a BK-Ca calcium activated
channel during pregnancy to relax the myometrium
amd prevent contractions [68,70-72]. hCG levels drop
during the final weeks of pregnancy. It has been sug-
gested that this drop may be the cause of increased con-
tractions in the weeks prior to parturition.
Four independent reports show that the blastocyst
preimplantation secretes hCG into the uterine space
which is taken up by hCG/LH receptors on the uterine
decidual surface. In response, the decidua is prepared
for impending implantation [77-80]. These non-vascular
communications by hCG are a critical part of a success-
ful pregnancy. Recent studies show the importance of
hCG preimplantation signaling [81-84]. hCG signaling
directly causes immunotolerance and angiogenesis at the
Table 3 Major discoveries in hCG assays or pregnancy tests 1930-1995 [1-35,61]
Year
published
Description Authors and reference
1930 First pregnancy test, the Zondek-Aschein Pregnancy Test Zondek B, Aschein S [55]
1960 First immunological pregnancy test, an antibody
agglutination test
Wide L, Gemzell CA [56]
1967 First hCG radioimmunoassay Aono T, Goldstein DP, Taymor ML, Dolch K [57]
1972 Discovery of hCGß radioimmunoassay, assay only detects
hCG
Vaitukaitis JL, Braunstein GD, Ross GF [58]
1984 First hCG radio-immunometric assay Armstrong EG, Ehrlich PH, Birken S, Schlatterer JP, Siris E, Hembree WE,
Canfield RE [59]
1995 Automated hCG chemiluminescent-immunometric assay Vankrieken L, Hertogh RE [60]
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uterine natural killer cells that play a key role in the
establishment of pregnancy [81-84].
Other new data shows other pre-pregnancy implanta-
tion function of hCG. Publications from Rao et al. and
by Gawronska et al. [84-86], show the presence of an
hCG/LH receptor (shown by presence of mRNA and
demonstration of receptor action) in human sperm and
in the fallopian tubes. The function of the hCG/LH
receptor in the in sperm is unclear. It possibly has some
relationship with fertility. hCG/LH receptor has recently
been demonstrated in adult women’s brain. CNS recep-
tors are present in several areas of the brain such as the
hippocampus, hypothalamus and brain stem [90,91].
The finding of an hCG receptor in these parts of the
brain may explain why hyperemesis gravidarum or nau-
sea and vomiting that occurs during normal pregnancy.
Exciting new research by multiple research groups is
finding hCG/LH receptors in fetal organs. Goldsmith et
al. [73], have found hCG/LH receptors in the fetal kid-
ney and liver. Rao et al. [30-32,74,75], have located
hCG/LH receptors in fetal lungs, liver, kidneys, spleen
and small and large intestines. Interestingly, this hCG/
LH receptor is present in the fetal organs but comple-
tely absent in the adult organs. Seemingly, hCG/LH
receptors disappear at birth.
It is suggested that hCG may promote organ growth
and differentiation in the fetus. The human fetus see-
mingly produces its own hCG from the fetal kidneys
and liver [73,76]. The concentrations in fetal circulation
are much lower than maternal concentrations,
suggesting that placental hCG secretion is directed
towards the maternal circulation only and is prevented
from entering into fetal circulation [76]. While the hCG
receptor has been shown in fetal organs, no function
has been directly demonstrated, just suggested. As such,
all the findings regarding the fetus have to be consid-
ered as just suggestions at this time. Unfortunately,
most animals do not make a form of hCG, making the
role of hCG in the fetus difficult to prove.
This review claims that there are 5 hCG variants with
independent biological activity [44]. There may actually
6 independent hCG variants when one considers fetal
hCG. It is made by fetal kidneys and liver [73,76] so
may not be structurally be similar to syncytiotrophoblast
sialylated hCG. Our supplies of fetal hCG may be lim-
ited to umbilical cord hormone. I am not sure that suffi-
cient fetal hCG will ever be collected to permit
structural analysis. Generally speaking only placental
and pituitary cells can make glycosylated hCG dimer,
other cells only produce free subunits. I wonder, is fetal
hCG a dimer, and normally glycosylated? It is only an
hCG/LH receptor that has been found in the fetus.
Does the fetus produce hyperglycosylated hCG as a
growth promoter, acting on a TGFß receptor?
Hyperglycosylated hCG is a super-glycosylated variant
of hCG. While hCG is made by fused placenta syncytio-
trophoblast cells, hyperglycosylated hCG is made by
root placental cytotrophoblast cells (13,46). As shown in
Figure 5 hyperglycosylated hCG is a variant of hCG
with double-size O-linked oligosaccharides and trian-
tennary (vs. biantennary) N-linked oligosaccharides.
Table 4 The biological functions of hCG during pregnancy
Function References
A. hCG
1. Promotion of corpus luteal progesterone production [6,9-11,88]
2. Angiogenesis of uterine vasculature [19-26]
3. Cytotrophoblast differentiation [18,61]
4. Immuno-suppression and blockage of phagocytosis of invading trophoblast cells [62-67,89]
5. Growth of uterus in line with fetal growth [68,69]
6. Quiescence of uterine muscle contraction [68,70-72]
7. Promotion of growth of fetal organs [30-32,73-76]
8. Umbilical cord growth and development [27-32]
9. Blastocysts signals uterine decidua prior to invasion regarding pending implantation [77-80]
10. hCG in sperm and receptors found in fallopian tubes suggesting pre-pregnancy communication [81-86]
11. hCG receptors in hippocampus and brain stem, may cause nausea and vomiting in pregnancy [90,91]
B. Hyperglycosylated hCG
1. Stimulates implantation by invasion of cytotrophoblast cells as occurs at implantation of pregnancy [13-16]
2. Stimulates growth of placenta by promoting growth of cytotrophoblast cells [13,14,16,17]
C. hCG and hyperglycosylated hCG together
1. Drives hemochorial placentation [87]
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unit and a 145 amino acid ß-subunit with hCG. Hyper-
glycosylated hCG is an extreme molecule, molecular
weight 42,800, 39% sugar by molecular weight. Hyper-
glycosylated hCG is the most acidic glycoprotein known
to humans, the peak acidity is pI 3.1.
Table 2 shows the concentration of hyperglycosylated
hCG in human serum during pregnancy. As shown,
hyperglycosylated hCG is the principal hCG form pro-
duced in early pregnancy. Hyperglycosylated hCG
accounts for 87% of total hCG in the 3 rd week of
gestation and 51% of total hCG during the 4
th week of
gestation, the proportion hyperglycosylated hCG rapidly
declines after this point. The high hyperglycosylated
hCG in early pregnancy is thought to be the driving sig-
nal of deep pregnancy implantation. Not all commercial
laboratory, research, point-of-care and home pregnancy
tests detect hyperglycosylated hCG equally with hCG.
This may make a test inappropriate for early pregnancy
detection [47]. In Laurence Cole PhD experience only
the Siemens Immulite series of tests is appropriate for
laboratory tests, only the Quidel and Beckman series of
tests are appropriate as Point-of-Care pregnancy tests
and only the Church and Dwight First Response and
Figure 5 The three dimensional structure of hyperglycosylated hCG [4]. In order to form crystals hCG was first deglycosylated. hCG and
hyperglycosylated hCG have identical amino acid sequence [1], yet vary in function. hCG binds the hCG/LH receptor while hyperglycosylated
hCG antagonizes a TGFß receptor [6-8]. As such the glycosylation (all removed) has to make a structural difference to the two hCG forms. This
difference is not shown. Oligosaccharide are added to the three dimensional structure assuming the carbohydrate structure observation of Elliott
et al. [1]. Oligosaccharides are charged so must project towards the surface of the molecule. L in oligosaccharides is N-acetylgalactosamine, A is
N-acetylglucosamine, S is sialic acid or N-acetyl-neuraminic acid, G is galactose, M is mannose and F is fucose.
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pregnancy tests. Hyperglycosylated hCG can be sepa-
rately detected to total hCG using the antibody B152
immunometric test, which only tested hyperglycosylated
hCG [92].
Hyperglycosylated hCG and hCG free ß-subunit are
interchangeable cancer promoters functioning by antag-
onizing a TGFß receptor [7,8]. It is thought that hyper-
glycosylated hCG produced in early pregnancy promotes
implantation by a similar mechanism, involving antagon-
ism of a TGFß receptor, blockage of apoptosis, and pro-
motion of metalloproteinase and collagenase production
[93-95].
Hyperglycosylated hCG has multiple clear functions in
human pregnancy implantation and promotion of cyto-
trophoblast growth (Table 4). Hyperglycosylated hCG is
demanded by pregnancy with it unique properties as a
TGFß antagonist to drive pregnancy implantation.
Implantation is driven in a cancer-like manner. In
humans implantation passed through the uterine
decidua, uterine stroma and connectictive tissue into the
uterine myometrium or muscle surrounding the uterine
endometrium. Placenta normally implants at 1/3
rd the
depth or the myometrium or approximately 40% of the
depth of the uterus. Implantation seemingly uses the
hyperglycosylated hCG-induced cytotrophoblastic metal-
loproteinases and collagenase activities to achieve its
goal [94,95]. Cytotrophoblast hyperglycosylated hCG as
an autocrine also promotes root placental cytotropho-
blast growth during the course of pregnancy to develop
and prime growing villous placental tissue (13,14,16,17).
Hyperglycosylated hCG, failing pregnancy and hypertense
pregnancy
As discussed in Section hCG, Hyperglycosylated hCG,
Hemochorial Placentation and Evolution, and Section
hCG, Hyperglycosylated hCG and pregnancy, human
hyperglycosylated hCG is the extreme end product of
evolution that drives pregnancy implantation to it
extreme, and drives production of hemochorial placenta-
tion to the extreme. Humans having an extreme mole-
cule to drive implantation are faced with the intricacies
and demands of an extreme molecule, so have to face a
high proportion of rejected pregnancies, this is miscar-
riage or spontaneous abortions (17% failure rate) and
biochemical pregnancies (25% failure rate) or 25% +
17% or 42% pregnancy failure rate [15,96]. Simian pri-
m a t e so n l yh a v ea n8 %f a i l u r er a t es i n c et h e yd on o t
have to cope with human hyperglycosylated hCG.
Scientist show that most biochemical pregnancies and
spontaneous abortion pregnancies, approximately two-
thirds, are due incomplete implantation of pregnancy
[97,98]. As shown by us in two studies examining 62
pregnancies and 127 pregnancies [15,99], all (100%) of
normal term pregnancies (81 and 42 total) produced
greater than 40% hyperglycosylated hCG (% of total
hCG) on the day of implantation. In contrast, only 8 of
36 and 7 of 20 biochemical and spontaneous aborting
pregnancies produced greater than 40% hyperglycosy-
lated hCG on the day of implantation. It is assumed
that the failures exceeding 40% hyperglycosylated hCG
are the rare genetic abnormalities and that the bulk, 28
of 36 and 13 of 20 pregnancies are pregnancy failures
due to improper implantation. It is concluded that
hyperglycosylated hCG is an absolute marker of bio-
chemical pregnancy and spontaneous abortion, and that
deficiency of hyperglycosylated hCG (< 50% hyperglyco-
sylated hCG) is the actual cause of human pregnancy
failures [15,99].
Unfortunately, to achieve the absolute differentiation
of term pregnancy and failing pregnancy the testing has
to be performed on the day of implantation of preg-
nancy. Detection of approximately 80% term pregnan-
cies is possible at later weeks of pregnancy [92,100].
The hyperglycosylated hCG test is licensed to Quest
Diagnostics Inc., and can be ordered from any world-
wide Quest Diagnostics laboratory. It also can be
o r d e r e df r o mt h eU S Ah C GR e f e r e n c eS e r v i c e .T h e
hyperglycosylated hCG test is also valuable as a high
sensitivity marker for Down Syndrome screening
[101,102]. This screening service is currently offered by
Quest Diagnostics Inc.
As published, The future sees prenatal screening being
expanded to pregnancy induced hypertension (PIH) and
preeclampsia screening, using a hyperglycosylated hCG
test. A study by Bahado-Singh and colleagues [103] and
more recent confirming studies by Brennan and collea-
gues (papers in preparation) shows that hyperglycosy-
lated hCG measurements may be invaluable for
screening women in the first and second trimester of
pregnancy for these two complication of pregnancy.
Today, preeclampsia is the biggest cause of maternal
death in pregnancy. Hyperglycosylated hCG promotes
hemochorial placentation formation [87], preeclampsia
and PIH are complication of ineffective hemochorial
placentation, thus it is marked by unduly low hypergly-
cosylated hCG. New hyperglycosylated hCG prenatal
screening tests will identify women at high risk for PIH
and preeclampsia.
Sulfated hCG and the menstrual cycle
Sulfated hCG produced by the pituitary is barely detect-
able during the menstrual cycle. Sulfated hCG parallels
LH during the menstrual cycle. In a recent study, at the
time of the LH peak, hCG level in 277 menstrual cycles
averaged 1.54 ± 0.90 mIU/ml [104]. In general, during
the menstrual cycle sulfated hCG levels are low,
approximately one fiftieth of circulating LH level
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exactly 50-fold more potent that LH [5]. As such sul-
fated hCG may perform a comparable job to LH in pro-
moting androstenedione production during the follicular
phase of the menstrual cycle, a comparable job in pro-
moting ovulation and corpus luteal formation. It may
also perform a comparable job to LH in promoting pro-
gesterone production in the luteal phase of the men-
strual cycle. All told, one can no longer correctly say
that LH promotes ovulation, it is LH plus sulfated hCG
[5,104-106].
During the menstrual cycle, hypothalamic gonadotro-
pin releasing hormone (GnRH) pulses stimulate follicle
stimulating hormone (FSH) ß-subunit and LH ß-subunit
genes (the a-subunit is produced in excess) in pituitary
gonadotrope cells. The problem is that on chromosome
19 there is a single LH ß-subunit gene located next to 8
hCG duplicated ß-subunit genes. GnRH bombards LH
ß-subunit gene and cannot help bombarding some of
the adjacent hCG ß-subunit genes leading to pituitary
hCG production. Gonadotrope cells can sulfate glyco-
proteins leading to partially sulfated hCG, LH and FSH.
In menopause, with the absence of steroid feedback to
the hypothalamus, GnRH pulse become maximal. The
result is promotion of vast excesses of LH, hCG and
FSH are produce by gonadotrope cell due to excessive
GnRH pulses. Serum LH increases from, 1-90 mIU/ml
to > 100 mIU/ml in menopause, serum FSH increases
from 1-29 IU/L to 30-200 IU/L in menopause, and
serum hCG from < 1 - 3 mIU/ml to 2-39 mIU/ml in
menopause. All told, pituitary sulfated hCG is very
detectable in a menopausal woman [104-108]. Perime-
nopause is the stage prior to menopause marked by oli-
gomenorrhea or irregular menstrual periods. Just as
perimenopause is marked by the start of raised LH and
FSH production, it is also marked by detectable hCG
levels.
Exceptional women can achieve pregnancy up to 60
years age. In general, women 40-55 years age are likely
to be in perimenopause, and those > 55 years age are in
menopause [107]. As reported, the range of hCG detec-
tion in non-pregnant menopausal women, > 55 years
age, is < 2 to 13.1 mIU/ml, in non-pregnant menstrual
women 18-40 years age is < 2 to 4.6 mIU/ml, and
potential perimenopause women is < 2 to 7.7 mIU/ml
[107]. In the USA hCG Reference Service experience,
h C Gl e v e l sa sh i g ha s2 9m I U / m l ,m e d i a n7 . 2m I U / m l
have been detected in perimenopause and as high as 33
mIU/ml, median 8.0 mIU/ml are detected in menopause
(Table 5). Higher hCG levels have been recorded, as
high as 39 mIU/ml, in women having oophorectomy
(Table 5).
The USA hCG Reference Service has examined 88
women producing pituitary sulfated hCG. This is a list
o fo n l yr e f e r r e dc a s e sa n di sn o tar a n d o ml i s to f
woman over 40 years old. Among the 88 cases, sulfated
hCG ranged from 1.8 mIU/ml to 39 mIU/ml [106]. In
menopausal cases the median level was 8.0 mIU/ml, in
perimenopausal cases the median was 7.2 mIU/ml and
in induced menopausal cases, women receiving oophor-
ectomy, the median was 6.3 mIU/ml.
Research by Gronowowski et al. [108], shows that
measurement of FSH levels is a powerful predictor of
pituitary sulfated hCG (FSH > 30 IU/L). The USA hCG
Reference Service started using FSH as a confirmation
of pituitary sulfated hCG one year ago. We both con-
firm and support the use of FSH testing to affirm the
diagnosis of pituitary hCG. Once a woman is diagnosed
as producing pituitary sulfated hCG, what do you do
next? The only answer is “nothing,” it is normal, it is
natural, you need to completely ignore it. A physician
can confirm that we are dealing with pituitary hCG, as
described above, by administering a high estrogen oral
contraceptive, to suppress hCG, for 3 weeks.
Table 5 Use of serum free ß-subunit (hCGß plus hyperglycosylated hCGß) and urine ß-core fragment as tumor markers
for detection of malignancies
Malignancy hCGß as a tumor marker ß-core fragment as a tumor marker
Number of Cases Serum hCGß (> 3 pmol/L) Number of Cases Urine ß-core fragment (> 3 pmol/L)
Bladder cancer 170 35% 102 48%
Cervical cancer 60 37%, 410 48%
Colorectal cancer 436 17%
Endometrial cancer 55 33% 157 47%
Lung cancer 243 18% 122 45%
Ovarian cancer 150 38% 207 66%
Pancreatic cancer 29 55%
Vulvar 64 41%
TOTAL 1164 Mean 30% 1027 Mean 48%
All averages are determined by combining total positive cases from multiple reports [109-130,132-138]
Cole Reproductive Biology and Endocrinology 2012, 10:24
http://www.rbej.com/content/10/1/24
Page 12 of 18Hyperglycosylated hCG, hCG free ß-subunit and cancer
My PhD at Medical College of Wisconsin was regarding
structure of this hCG-variant produced by 2 cervical
cancer cell lines, DoT and Caski. As shown, these cell
lines produce a invariably glycosylated variant of hCG
free ß-subunit. Soon after getting my PhD, I went on to
a postdoctoral fellowship at University of Michigan in
A n nA r b o ra n ds h o w e dt h a th C Gf r e eß - s u b u n i tw a sa
tumor marker present in culture fluids, serum and
urine, and patented hCG free ß-subunit and its variants
including ß-core fragment as a tumor markers [109].
This patent was licensed by Ciba-Corning Laboratories,
the predecessor to Quest Diagnostics 1985-1999,
Multiple studies in the early 1980s showed that serum
hCG free ß-subunit and urine ß-core fragment its degra-
dation product, were tumor marker for all cancers
(Table 5). As shown and averaged over multiple studies
[109-125] (Table 5), hCG free ß-subunit and ß-core
fragment marked a proportion of all malignancies. All
told, hCG free ß-subunit marked 30% of 1,164 malig-
nancies in serum tests, at the extremes, 17% of colorec-
tal cancers, and 38% of ovarian cancers [109-125] (Table
5). All told and averaged, hCG ß-core fragment marked
48% of 1,027 malignancies in urine tests, at the
extremes, 45% of lung cancers, and 66% of ovarian can-
cers (Table 5) [109-125].
In the years that followed Acevedo and Krichevsky
[126] and Regelson [127] used cancer membrane flow
cytometry methods to show that all advanced cancers
produced an hCG free ß-subunit variant. An investiga-
tion into hCG degradation at that time showed that
hCG free ß-subunit (circulating 1/2-life 0.72 h) is
removed from the circulation much more rapidly than
hCG (circulating 1/2-life 36 h) [128]. Research showed
that hCG free ß-subunit is nicked upon entering the cir-
culation, and possibly loses its C-terminal peptide
[129,130]. As such hCG free ß-subunit had a circulating
1/2-life of just seconds, seconds before it is degraded
and excreted in the kidney, or removed by the liver.
With the miniscule circulating survival time, the claim
that all malignancies produced hCG free ß-subunit,
while it could only be detected in the serum in just 30%
of cases made sense. Clearly, most of the hCG free ß-
subunit produced by cancers was cleared rapidly and
was undetectable as a tumor marker.
Research into choriocarcinoma showed that this can-
cer produced hyperglycosylated hCG [1,131]. It was not
until the mid-2000s that it was shown that hyperglyco-
sylated hCG was a separate and independent molecule
to hCG acting on cytotrophoblast cells in pregnancy
implantation, and in choriocarcinoma cells [13,14]. As
demonstrated, hyperglycosylated hCG directly promoted
choriocarcinoma cytotrophoblast cell growth (in cell cul-
ture) and invasion (in Matrigel chambers). Regular hCG
had no effect [13,14]. When choriocarcinoma cells were
transplanted into nude mice cancer grew rapidly. Cancer
cell growth and malignancy could be totally suppressed,
oncostasis, by treating the nude mice with hyperglycosy-
lated hCG antibody [13,14]. Clearly, hyperglycosylated
hCG was the single driving signal of choriocarcinoma. It
was then shown that ovarian and testicular germ cell
malignancies took on choriocarcinoma-like cytotropho-
blast morphology, producing high concentrations of
hyperglycosylated hCG, like choriocarcinoma, and dri-
ven by hyperglycosylated hCG like choriocarcinoma
cells [14].
While research with hyperglycosylated hCG and chor-
iocarcinoma was ongoing in the USA, research in Eur-
ope was continuing to investigate hCG free ß-subunit
and other malignancies. As found in the 1990s, the
detection of hCG free ß-subunit in serum was a marker
of poor prognosis of cancer [132]. Later, it was shown
that hCG free ß-subunit secreted by cancer cells directly
stimulated cancer cell growth [7,133-138]. hCG free ß-
subunit blocked apoptosis in cancer cells and enhanced
growth and malignancy [7,133-138]. In 2000, Stephen
Butler PhD in Europe showed that hCG free ß-subunit
produced by bladder cancer cells bound and antago-
nized a TGFß receptor on cancer cells [7].
Recently, I examined hyperglycosylated hCG and 2
choriocarcinoma cell lines, and hCG free ß-subunit and
2 bladder cancer lines and 2 endometrial cancer cell
lines [8]. I confirmed, hyperglycosylated hCG promoted
growth of both choriocarcinoma cell lines and hCG free
ß-subunit promoted growth of both bladder and endo-
metrial cancer cell lines [8]. Intriguingly, they were
interchangeable and could take each other’sr o l e s ,
hyperglycosylated hCG could promote bladder and
endometrial cancer, and hCG free ß-subunit could pro-
mote choriocarcinoma [8]. It was rapidly inferred that
both antagonize a TGFß receptor making them
interchangeable.
This research seemingly tied together our knowledge
regarding hCG and cancer, interlinking the general can-
cer stories of Europe and the choriocarcinoma amd
germ cell cancer stories of the USA. The story of hCG
and cancer was very much enhanced and confirmed by
ongoing clinical trials with hCG vaccines and advanced
malignancies. Three companies, Celldex, CG Therapeu-
tics and MCI BioPharma Inc. started in 2000 testing a
synthetic hCGß vaccine in treating advanced cancer
cases [139-144]. Results were very exciting, with the
finding that hCGß vaccines are considerably extending
lives of advanced cancer patients. For example, examin-
ing the clinical trial with hCGß vaccine and colorectal
cancers [141], the average survival of those with optimal
antibody response was 45 weeks, compared to just 24
weeks in those without optimal response (p = 0.0003).
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tially double longevity. Similar results have been
reported with prostate cancer, lung cancer and breast
cancer.
In conclusion, there are seemingly 2 kinds of cancer as
relates to hCG variants. Type 1 is a cancer of hypergly-
cosylated hCG producing cells, choriocarcinoma, gesta-
tional trophoblastic neoplasm, and ovarian and
testicular germ cell cancers. This type of cancer pro-
duces hyperglycosylated hCG from the start of malig-
nancy. Hyperglycosylated hCG seemingly work through
a mechanism involving antagonism of TGFß (proposed
mechanism, Figure 6) [7,8]. This type of cancer is
seemingly modulated completely by hyperglycosylated
hCG, its growth, metastases and grade.
The second type of cancer was seeming represented
by all other human malignancies, include lung cancer,
breast cancer, leukemia, lymphoma and so on. These
cancers start out as transformed cell driven by an hCG-
independent process. As the cancer progresses and
becomes advanced it is able to express the hCG ß-subu-
nit gene and make hCG free ß-subunit. The hCG free
ß-subunit driven TGFß antagonism mechanism (pro-
posed mechanism, Figure 6) takes over control of the
cancer, as indicated by the vaccine studies, and has
complete control of the advanced disease. Based on the
Figure 6 Proposed pathways of free ß-subunit and hyperglycosylated hCG in advanced cancer cases. As illustrated, free ß-subunit and
hyperglycosylated hCG are hCG variants with exposed TGFß binding structures [1-4,6], these are autocrines which antagonize the TGFß receptor,
promoting cell growth and blocking cell apoptosis. As a result of the antagonism, collagenases and metalloproteinases are produced by cells
[94,95]. As illustrated, cells secrete hCG free ß-subunit or hyperglycosylated hCG. This enters the circulation and rotates around the body. hCG
free ß-subunit of hyperglycosylated hCG then bind back on a receptor on the cancer cells, a TGFß receptor, and antagonize this receptor. As a
result cell growth is promoted, and cell apoptosis is blocked. Cell secrete collagenases and metalloproteinases.
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hCG ß-subunit antibody may be a future answer to
human cancer treatment. Vaccine only works in people
with a good functioning immune system. This is where
hCG ß-subunit antibody may shine. I believe that hCG
ß-subunit antibody based on nude mouse experiments
[13,14], could someday cure Type 1 cancers, and could
seemingly offers greatly improved treatment and
improved longevity to all Type 2 malignancies.
Conclusions
hCG is a wonder of today’s science. It firstly is extreme
molecule, including features such as the most acidic
molecule, the most glycosylated molecule and the long-
est circulating half life. It secondly is unique with multi-
ple variants of hCG having independent functions, and
hCG variants binding 2 separate receptors, hLG/LH
receptor and TGFß receptor. hCG needs to be consid-
ered as a placental hormone and autocrine, a pituitary
hormone and a major cancer promoter.
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